Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;17(6):39-45.
doi: 10.3747/co.v17i6.670.

Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer

C Cripps  1 , S Gill, S Ahmed, B Colwell, S Dowden, H Kennecke, J Maroun, B Samson, M Thirlwell, R Wong
Affiliations

Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer

C Cripps et al. Curr Oncol. 2010 Nov.

Abstract

In January 2010, a panel of Canadian oncologists with particular expertise in colorectal cancer (crc) gathered to develop a consensus guideline on the use of therapies against the epidermal growth factor receptor (egfr) in the management of metastatic crc (mcrc). This paper uses a case-based approach to summarize the consensus recommendations developed during that meeting.These are the consensus recommendations:Testing for the KRAS status of the tumour should be performed as soon as an egfr inhibitor is being considered as an option for treatment.Anti-egfr therapies are not recommended for the treatment of patients with tumours showing mutated KRAS status.For a patient with wild-type KRAS and an Eastern Cooperative Oncology Group status of 0-2, whose mcrc has previously been treated with a fluoropyrimidine, irinotecan, and oxaliplatin, switching to an egfr inhibitor is a recommended strategy.Cetuximab, cetuximab plus irinotecan, and panitumumab are all options for third-line therapy in patients with wild-type KRAS, provided that tolerability is acceptable.

Keywords: Anti-egfr; Canadian consensus; cetuximab; metastatic colorectal cancer; panitumumab.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Overall survival: cetuximab compared with best supportive care alone in patients with the wild-type KRAS gene . Copyright 2008, Massachusetts Medical Society. All rights reserved.
FIGURE 2
FIGURE 2
Progression-free survival: panitumumab compared with best supportive care (bsc) alone in patients with a wild-type KRAS gene . Reprinted with permission. Copyright 2008, American Society of Clinical Oncology. All rights reserved.
See this image and copyright information in PMC

References

    1. Bristol–Myers Squibb Canada. Erbitux (Cetuximab) [product monograph] Montreal, QC: Bristol–Myers Squibb Canada; Feb 1, 2010.
    1. Amgen Canada. Vectibix (Panitumumab) [product mono-graph] Mississauga, ON: Amgen Canada; Feb 26, 2010. [Available online at: www.amgen.ca/Vectibix_PM.pdf; cited October 8, 2010]
    1. Karapetis CS, Khambata–Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65. - PubMed
    1. van Cutsem E, Peeters M, Siena S, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64. - PubMed
    1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34. - PubMed